Vertex Pharmaceuticals Incorpor found using ticker (VRTX) now have 22 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 300 and 224 calculating the average target price we see 267.91. Now with the previous closing price of 224.49 this indicates there is a potential upside of 19.3%. There is a 50 day moving average of 227.77 and the 200 day MA is 211.39. The market cap for the company is $56,324m. Find out more information at:

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for the treatment of cystic fibrosis (CF). The company markets TRIKAFTA, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF who have specific mutations in their CF transmembrane conductance regulator gene. It is also developing VX-814, which is in Phase II clinical trial and VX-864 that is in Phase I clinical trial for the treatment of alpha-1 antitrypsin deficiency; VX-147 for treating kidney diseases; and CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases. In addition, the company develops VX-150, an inhibitor that is in Phase II clinical trial for acute, neuropathic, and musculoskeletal pain; and VX-561, a potentiator that is in Phase II clinical development; as well as evaluating VX-121, an additional corrector. It sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. The company has collaborations with CRISPR Therapeutics AG; Kymera Therapeutics Inc.; Parion Sciences; BioAxone Biosciences; Merck KGaA; Janssen Pharmaceuticals; Arbor Biotechnologies; Moderna Therapeutics; Genomics plc; X-Chem; Molecular Templates; and Ribometrix The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Join us on our new LinkedIn page

Follow us on LinkedIn

Source link